Colorectal Cancer

>

Latest News

Exercise-Based Regimen Shows Efficacy Promise in CRC
Exercise-Based Regimen Shows Efficacy Promise in CRC

June 30th 2025

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.
Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

June 28th 2025

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.
Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC

June 23rd 2025

Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases
Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

June 20th 2025

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC
Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

June 17th 2025

More News


Site Logo

Anti-EGFR Mechanism of Action: Antitumor Effect and Underlying Cause of Adverse Events

April 29th 2006

Overexpression of the epidermal growth factor receptor (EGFR) is correlated with poor prognosis in many human cancers. Two main classes of anticancer agents affect the EGFR: those targeting the extracellular ligand-binding domain and those that block the intracellular tyrosine kinase (TK) domain. Cetuximab (Erbitux) is a mouse/human chimeric monoclonal antibody that targets the ligand-binding domain of the EGFR, whereas erlotinib (Tarceva) and gefitinib (Iressa) are small-molecule TK inhibitors. Common toxicities of agents targeting the EGFR differ from those associated with traditional chemotherapy. Given the common pathway through which these agents work, some adverse events are similar. Many patients treated with these agents develop an acne-like rash on the face and upper body, most likely related to keratinocyte alterations and hair follicle proliferation and maturation. Although clinical manifestation of this reaction closely resembles acne vulgaris, the histology is more similar to infectious folliculitis. Other adverse events appear to be related to a drug class or individual agent. For example, interstitial lung disease is a rare but potentially fatal reaction that has been reported with gefitinib. Hypomagnesemia reported in association with cetuximab may be related to EGFR blockade in the kidney. Anaphylactic or anaphylactoid infusion reactions are also seen with cetuximab, as with other monoclonal antibodies.